Skip to main content
FLNA logo

FLNA · Filana Therapeutics, Inc.

Track FLNA — free
$0.93 +0.01 (+0.65%) At close · Aug 28
Market Cap
$44.88M
Shares
48.31M

Named-executive compensation from the company's DEF 14A proxy statements — salary, bonus, stock and option awards, non-equity incentive, and the company-reported total per executive per fiscal year, exactly as disclosed in the Summary Compensation Table.

Fiscal 2025
Executive Total
Richard J. Barry $1,520,035
Eric J. Schoen $830,010
R. Christopher Cook $818,985
Fiscal 2024
Executive Total
Richard J. Barry $16,729,425
Eric J. Schoen $3,850,772
Remi Barbier $3,685,803
James W. Kupiec $3,306,128
R. Christopher Cook $3,295,128
Fiscal 2023
Executive Total
Remi Barbier $6,263,038
Eric J. Schoen $2,992,825
James W. Kupiec $2,967,825
R. Christopher Cook $1,269,275
Richard J. Barry $546,155
Fiscal 2022
Executive Total
R. Christopher Cook $3,656,062
Remi Barbier $1,114,998
Nadav Friedmann $479,167
Eric J. Schoen $426,610
James W. Kupiec $400,000
Fiscal 2021
Executive Total
Remi Barbier $1,741,120
Eric J. Schoen $776,932
Nadav Friedmann $765,000
James W. Kupiec $473,579
Fiscal 2020
Executive Total
Remi Barbier $936,120
Nadav Friedmann $345,000

Executive changes

Person Change Filed
Claude Nicaise, M.D. Appointed 2026-06-15
Pierre Gravier Appointed 2026-06-15
Richard J. Barry Appointed 2026-06-15
Dawn Carter Bir Appointed 2025-10-22
Michael J. O’Donnell Appointed 2025-05-27
Robert Anderson, Jr. Appointed 2025-05-27
R. Christopher Cook Appointed 2025-04-21
James W. Kupiec, M.D. Retired 2025-04-21
Claude Nicaise, M.D. Appointed 2024-09-09
Richard (Rick) Barry Appointed 2024-09-09
Lindsay Burns Resigned 2024-07-17
Richard J. Barry Appointed 2024-07-17
Remi Barbier Resigned 2024-07-17
Remi Barbier Resigned 2024-07-17
Remi Barbier Resigned 2024-07-17
Pierre Gravier Appointed 2023-12-11
Robert Anderson, Jr. Appointed 2023-12-11
Dr. Claude Nicaise Appointed 2023-12-11
Richard J. Barry Appointed 2021-06-14
James W. Kupiec Appointed 2021-01-06
Saira Ramasastry Resigned 2020-06-19
Key facts CIK 1069530 CUSIP 14817C107 13F (30d) 69 filings 69 filers Visit website Investor relations